Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell to showcase groundbreaking findings at ASCO 2024.
Details here: https://www.globenewswire.com/.../BriaCell-Announces-Oral...
Dr. Saranya Chumsri from Mayo Clinic leads an oral presentation on the promising Bria-IMT™ in metastatic breast cancer. Additionally, two posters will feature insights into ongoing clinical studies.
#ASCO2024 #CancerResearch #stockstowatch $BCTX
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-announces-strong-clinical-data-130000153.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX) Up 10% on News
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Up 10%
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles
Stock up 10% so far on this news.
Read more about it https://bit.ly/3RNwgq1
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Stock up 10% so far on this news.
Endexx® Corporation (OTCQB: EDXC) Featured on SmallCapVoice.com HYLA Targets 300% Growth Rate Per Year
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
Endexx® Corporation (OTCQB: EDXC) HYLA Targets 300% Growth Rate Per Year
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
EDXC HYLA Targets 300% Growth Rate Per Year Endexx® Corporation (OTCQB: EDXC) Featured on SmallCapVoice.com
Exclusive interview with Todd Davis, CEO of Endexx Corporation, and Nick Mehdi, CEO of HYLA! Exciting discussions about the groundbreaking strides HYLA has made for OTCQB: EDXC
Tune in for insights into future plans
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) News!
🎗October is Breast Cancer Awareness 🎗
BriaCell is leading the fight with recent study showing survival rate of 13.5 months, offering hope in advanced metastatic breast cancer.
Find out more about the month and BriaCells progress here: https://www.globenewswire.com/news-release/2023/10/20/2764046/0/en/October-is-Breast-Cancer-Awareness-Month-BriaCell-is-Leading-the-Fight-with-its-Innovative-Technology.html
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
#Phase3Study #CancerCare
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
(Nasdaq: BCTX) (TSX: BCT) BriaCell teams up with New York Cancer & Blood Specialists for Phase 3 study of Bria-IMT™ in advanced breast cancer. Together, pioneering new paths in cancer care at one of the nation’s leading cancer centers.
https://globenewswire.com/news-release/2023/10/04/2754618/0/en/BriaCell-Partners-with-New-York-Cancer-Blood-Specialists-NYCBS-for-Pivotal-Phase-3-Study-of-Bria-IMT-in-Advanced-Breast-Cancer.html
#Phase3Study #CancerCare
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-Median Survival: 13.5 months (vs. 6.7-9.8)
-21 of 29 terminal patients treated since 2022 are alive
-No toxicities reported
(Nasdaq: BCTX) becoming a ray of hope in the toughest fight. #CancerBreakthrough
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-21 of 29 terminal patients treated since 2022 are alive
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
News Alert: BriaCell (Nasdaq: BCTX) (TSX: BCT) Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
-21 of 29 terminal patients treated since 2022 are alive
https://finance.yahoo.com/news/briacell-reports-benchmark-beating-patient-110000318.html
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
BCTX Big News Today
FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.
FDA has approved the study design, the primary and secondary endpoints, and patient population in BriaCell’s upcoming pivotal registration clinical study. The study will include advanced metastatic breast cancer patients who have exhausted all other treatment options.
The trial will be a randomized, open-label study comparing the Bria-IMT™ combination regimen with an immune check point inhibitor in one arm with treatment of physicians’ choice in another arm in advanced metastatic breast cancer. A third smaller arm with the Bria-IMT™ regimen alone will be included in the study to address FDA’s combination drug assessment requirements. Upon achieving statistically significant milestones, BriaCell may apply for full approval of the Bria-IMT™ combination regimen following the Biologics Licensing Application (BLA) filing process.
“FDA approval of our study design represents a major milestone towards our goal of making a huge impact in the lives of advanced metastatic breast cancer patients who have failed currently approved therapies,” stated Dr. William V. Williams, BriaCell’s President and CEO.
“We are extremely grateful that the FDA Office of Oncologic Diseases has approved our strategy and has provided us with a route to accelerate the development of our novel immunotherapy in this difficult-to-treat patient population. A successful study may significantly transform the approach to treat advanced breast cancer,” added Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We are working closely with FDA to further accelerate the development of our lead candidate and eventual market authorization.”
Patient recruitment and dosing will commence in summer 2023.
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://finance.yahoo.com/news/susglobal-energy-corp-director-former-120000549.html
#Stocks #OTCMarkets #OTC
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://finance.yahoo.com/news/susglobal-energy-corp-director-former-120000549.html
#Stocks #OTCMarkets #OTC
Don't miss our latest interview with Bruce Rintoul, a key Member of the Board of Directors at SusGlobal Energy Corp (OTCQB: SNRG).
Listen to the full interview here: https://www.accesswire.com/.../SusGlobal-Energy-Corp...
#Stocks #OTCMarkets #OTC
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$BCTX $15 Price Target
Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.
Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx
#Stocks #StocksToWatch #StockMarket
$SNRG SusGlobal Energy Corp. Reports Fourth Quarter and Full Year 2022 Financial Results
Great news for shareholders of SusGlobal Energy Corp (OTCQB: SNRG)!
The Company’s Fourth Quarter and Full Year 2022 Financial Results are in.
Check out their press release here: https://finance.yahoo.com/news/susglobal-energy-corp-reports-fourth-123000829.html
#Stocks #StocksInFocus #OTC
$SNRG SusGlobal Energy Corp. Reports Fourth Quarter and Full Year 2022 Financial Results
Great news for shareholders of SusGlobal Energy Corp (OTCQB: SNRG)!
The Company’s Fourth Quarter and Full Year 2022 Financial Results are in.
Check out their press release here: https://finance.yahoo.com/news/susglobal-energy-corp-reports-fourth-123000829.html
#Stocks #StocksInFocus #OTC
$BCTX $25 Price Target and Stock is Breaking Out
Big news for BriaCell (Nasdaq: BCTX) investors: H.C. Wainwright & Co. issues a buy rating and a $25 price target for this innovative #biotech company.
Is $BCTX on your watchlist?
#Stocks #StockMarket
$BCTX New Buy Rating with $25 price target from H.C. Wainwright!
Big news for BriaCell (Nasdaq: BCTX) investors: H.C. Wainwright & Co. issues a buy rating and a $25 price target for this innovative #biotech company.
Is $BCTX on your watchlist?
#Stocks #StockMarket
$MWWC Marketing Worldwide Corporation Media Specialist Talks Formula for Success and Hollywood After Dark in Video Interview with SmallCapVoice.com
AUSTIN, TX / ACCESSWIRE / April 6, 2023 / SmallCapVoice.com Inc. ("SCV") announces the availability of its latest interview with Robert Blagman, media pioneer and specialist for Marketing Worldwide Corporation (OTC PINK:MWWC) ("the Company"), to discuss the divergent paths to success and failure in television.
Speaking with SCV's Stuart Smith, Blagman taps into his 40+ of experience in the media industry, explaining how his formula for success will lead MWWC to hit its viewership and advertising goals.
"What we do - and what I've been doing for decades - is connecting directly with TV station executives from all around the world seeking out what programming they are looking for in their home market … We also talk with consumers and follow social media trends to secure our path to success. Most importantly we secure a critical mass of TV stations, from around the world, and contract them to carry our series for a full run (not just a "pilot" episode scenario).
With our unique ability to reach more than one third of the planet's consumers via our media partners (TV Stations, Networks and digital platforms)… we then source targeted advertisers and sponsors. Advertisers will always pursue as many "eyeballs" as possible - AND that's what we deliver en masse. We also exploit social media to advance our program's appeal. Included as well is the sale of program and celebrity merchandise mixed with crowd appealing promotions. We leave nothing to chance."
"It's more than a concept", he adds. "It takes calculation and focused effort to execute the plan and create content that resonates throughout the world. This is a tested method that works and has worked for decades. We create media that is culturally relevant to all targeted demographics."
The interview concludes with reference to MWWC's upcoming Hollywood After Dark. A live TV and digital series that will gather celebrities, singers, professional athletes and entertainers for an uncensored, invitation-only event that allows audiences a sneak peek into the socializing world of fame in Hollywood. Hollywood After Dark, which is being funded by MWWC, will film its first episode by July 2023 and will begin taping promotional videos as early as May. Hollywood After Dark will be presented to a global audience via TV stations and pay-per-view (in select countries). We'll be formally announcing the series at the globally renowned NATPE Budapest media conference in June. https://budapest.natpe.com/
Watch the full interview at
$MWWC Marketing Worldwide Corporation Media Specialist Talks Formula for Success and Hollywood After Dark in Video Interview with SmallCapVoice.com
AUSTIN, TX / ACCESSWIRE / April 6, 2023 / SmallCapVoice.com Inc. ("SCV") announces the availability of its latest interview with Robert Blagman, media pioneer and specialist for Marketing Worldwide Corporation (OTC PINK:MWWC) ("the Company"), to discuss the divergent paths to success and failure in television.
Speaking with SCV's Stuart Smith, Blagman taps into his 40+ of experience in the media industry, explaining how his formula for success will lead MWWC to hit its viewership and advertising goals.
"What we do - and what I've been doing for decades - is connecting directly with TV station executives from all around the world seeking out what programming they are looking for in their home market … We also talk with consumers and follow social media trends to secure our path to success. Most importantly we secure a critical mass of TV stations, from around the world, and contract them to carry our series for a full run (not just a "pilot" episode scenario).
With our unique ability to reach more than one third of the planet's consumers via our media partners (TV Stations, Networks and digital platforms)… we then source targeted advertisers and sponsors. Advertisers will always pursue as many "eyeballs" as possible - AND that's what we deliver en masse. We also exploit social media to advance our program's appeal. Included as well is the sale of program and celebrity merchandise mixed with crowd appealing promotions. We leave nothing to chance."
"It's more than a concept", he adds. "It takes calculation and focused effort to execute the plan and create content that resonates throughout the world. This is a tested method that works and has worked for decades. We create media that is culturally relevant to all targeted demographics."
The interview concludes with reference to MWWC's upcoming Hollywood After Dark. A live TV and digital series that will gather celebrities, singers, professional athletes and entertainers for an uncensored, invitation-only event that allows audiences a sneak peek into the socializing world of fame in Hollywood. Hollywood After Dark, which is being funded by MWWC, will film its first episode by July 2023 and will begin taping promotional videos as early as May. Hollywood After Dark will be presented to a global audience via TV stations and pay-per-view (in select countries). We'll be formally announcing the series at the globally renowned NATPE Budapest media conference in June. https://budapest.natpe.com/
Watch the full interview at